Organization

China Medical University

Aliases
China Medical University, China

16 clinical trials

2 abstracts

Abstract
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
Org: University Medical Center Mainz, University Grenoble Alpes, CHU Grenoble Alpes, Institute for Advanced Biosciences, Kindai University Faculty of Medicine, Osaka-Sayama, Japan,